Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Extended Management and Measurement of Autism

ClinicalTrials.gov ID: NCT00787111

Public ClinicalTrials.gov record NCT00787111. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 18, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Extended Management & Measurement of Autism (Emma): An Open-Label, Follow-On Study to Investigate the Safety and Impact on Developmental Trajectory of 18 Months Treatment With Fluoxetine Orally Dissolving Tablet (Odt) In Childhood and Adolescent Autistic Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This open-label research study will continue to monitor the safety of fluoxetine in children after their completion of a previous double-blind placebo controlled clinical study, with fluoxetine. The study will also look at the effect of fluoxetine on IQ (Intelligence Quotient) over an 18 month period.

Study identification

NCT ID
NCT00787111
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neuropharm
Industry
Enrollment
128 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
5 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2008
Primary completion
Mar 31, 2009
Completion
Mar 31, 2009
Last update posted
Feb 22, 2010

2008 – 2009

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Southwest Autism Research and Resource Centre Phoenix Arizona 85006
University of California Davis Sacramento California 95817
Institute for Behavioral Medicine Smyrna Georgia 30080
University of Illinois Chicago Illinois 60637-1448
AMR-Baber Research Inc. Naperville Illinois 60563
Harvard Medical School Medford Massachusetts 02155
Children's Hospital of Michigan Detroit Michigan 48201
CRCNJ Voorhees Township New Jersey 08043
Long Island Jewish Hospital Bethpage New York 11714
Mount Sinai School of Medicine New York New York 10029
University of North Carolina Chapel Hill North Carolina 27514
Ohio State University Columbus Ohio 43210
Seattle Children's Hosptial University of Washington Seattle Washington 98105-0371

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00787111, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 22, 2010 · Synced Sep 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00787111 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →